In conclusion, TRIM17 promotes FTO degradation via ubiquitination, a post-translational modification, and positively modulates the AKT/mTOR signaling pathway, thereby enhancing osteosarcoma malignancy. The gene discussed is MTOR; the disease is osteosarcoma.